News Search Results
May 12, 2025, 03:59 ET Citrus Aurantium Extract Market to Reach $4,339.2 Million by 2027 in short term and $5,671.7 million by 2034 Globally, at 3.8% CAGR: Allied Market Research
aurantium extract industry include Activ'Inside, Foodchem International Corporation, Herbal Creations, Innophos, NaturMed Scientific, Nutra Green Biotechnology Co., Ltd., Nutraceuticals Group Europe Ltd., Shaanxi Jiahe Phytochem Co., Ltd. (Jiaherb), Sinerga S.p.A., and Xi'an Sost Biotech Co., Ltd. Key
More news about: Allied Market Research
May 12, 2025, 03:30 ET Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
May 12, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary lateral CAR platform,
More news about: Leucid Bio
May 12, 2025, 01:41 ET CJ Foods Names Dr. Gregory Yep as its New Chief Executive Officer
Gregory Yep as its new chief executive officer. Yep has more than three decades of diverse leadership in food science, nutrition, and biotechnology across numerous consumer goods and food-related multinational businesses. Dr. Yep assumes leadership at a transformative moment for CJ Foods as
More news about: CJ Foods
May 11, 2025, 18:01 ET Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 09, 2025, 20:38 ET Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's investor presentation demonstrates that Deep Track fundamentally does not understand how to run a successful commercial stage biotechnology company. Deep Track's one-dimensional plan to strip-mine Dynavax ignores market realities and the clear need to have a diversified portfolio and
More news about: Dynavax Technologies
May 09, 2025, 16:01 ET AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
May 09, 2025, 14:06 ET BUILDING HOPE CELEBRATES IMPACT SUMMIT SUCCESS AND AWARDS $188,500 IN GRANTS
them to become more than they ever thought they would be, Sallie B. Howard offers specialized programs including biotechnology training and study abroad opportunities. Its core value system—Perseverance, Respect, Integrity, Discipline, and Excellence (PRIDE)—shapes a high-expectation
More news about: Building Hope
May 09, 2025, 10:01 ET In Vitro Diagnostics Market worth US$157,632.5 million by 2030 with 7.6% CAGR | MarketsandMarkets™
specializing in donor-derived CAR-T cell therapies. Danaher (US): Danaher has a broad product portfolio in segments like Biotechnology, Life Sciences, and Diagnostics. The company markets its IVD products in over 100 markets directly or indirectly. The Diagnostics segment provides
More news about: MarketsandMarkets
May 09, 2025, 08:01 ET Anivive's Dr. Edward Robb Presents Innovative Valley Fever Vaccine Research at World Vaccine Congress 2025
Anivive.com About Anivive Lifesciences Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable
More news about: Anivive Lifesciences Inc.
May 09, 2025, 08:01 ET MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds
More news about: MetaVia Inc.
May 09, 2025, 08:00 ET Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 09, 2025, 07:30 ET Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
May 09, 2025, 07:30 ET Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
May 09, 2025, 07:00 ET SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025
May 9, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that one abstract on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug
More news about: SystImmune, Inc.
May 09, 2025, 05:45 ET Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
May 08, 2025, 23:27 ET Pureture Scales Emulsifier-Free Protein, Redefining What Casein Can Be
requiredUp to 30% lower cost than dairy-derived caseinAbout Pureture Pureture is a New York–based food biotechnology company developing next-generation functional protein ingredients through non-GMO strain engineering, controlled culturing, and clean-label formulation
More news about: Pureture
May 08, 2025, 22:19 ET Palatin Technologies Announces Closing of Reduced Public Offering
complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking
More news about: Palatin Technologies, Inc.
May 08, 2025, 17:40 ET Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB
READ THE FULL REPORT HERE.As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently-acquired lead asset, Budoprutug,
More news about: CorpGov
May 08, 2025, 17:31 ET LUPKYNIS Strengthens Market Position as Demand for Lupus Nephritis Treatment Grows | DelveInsight
landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio,
More news about: DelveInsight Business Research, LLP
May 08, 2025, 16:40 ET SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
enthusiastically welcome Lee to our leadership team." Mr. Anderson comes to Sera with a robust track record in leadership roles within the biotechnology and diagnostics sector, primarily highlighted by his transformative tenure at Genomic Health and Exact Sciences. At Genomic Health, which was later
More news about: Sera Prognostics, Inc.
May 08, 2025, 16:39 ET Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
May 08, 2025, 16:15 ET KARMA BIOSCIENCES ANNOUNCES PATENT APPLICATIONS FOR NOVEL NASALLY-ADMINISTERED PDE-5 INHIBITORS
products to market," said Cunningham. About Karma Biosciences: Karma Biosciences is a Corvallis, Oregon based biotechnology company dedicated to creating and testing novel pharmaceutical formulations using advanced excipients to improve drug delivery.
More news about: Karma Biosciences
May 08, 2025, 16:15 ET Nektar Therapeutics Reports First Quarter 2025 Financial Results
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 08, 2025, 16:05 ET Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
May 08, 2025, 16:05 ET Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience
More news about: Spyre Therapeutics, Inc.